Media ReleasesCellmid Limited

View All Cellmid Limited News

Cellmid Ltd, Key Antibody Patent Granted in Japan

-  Japanese patent for treating autoimmune disorders using midkine antibodies granted
-  Novel mechanism of action boosting regulatory T cells
-  USA patent already granted in 2012

SYDNEY, Friday, 18 October 2013: Cellmid Limited (ASX:CDY) advises that the Japanese Patent Office (JPO) granted Cellmid’s patent application JP 2007-544236 "Method for Treatment or Prevention of Diseases Associated with a Functional Disorder of Regulatory T Cells".

JP 2007-544236 is a member of a key patent family in Cellmid’s antibody patent portfolio. Its grant adds yet another layer of intellectual property protection to Cellmid’s anti-midkine antibody (MK antibody) programme.

JP 2007-544236 covers the use of MK antibodies to increase the number of regulatory T cells (Tregs). Tregs are central controllers of autoimmune responses; when Treg numbers are too low, the body’s immune system can attack its own tissues, leaving subjects vulnerable to autoimmune diseases. Increasing the Treg numbers can mitigate such autoimmune attack.

For further information please download PDF below:

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.